To Get Full Access :

Ogsiveo

Ogsiveo is an oral therapy for adults with desmoid tumors that are actively progressing. It targets a protein involved in tumor formation, helping reduce tumor size and manage symptoms.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Nirogacestat
  • Innovator :

    SPRINGWORKS THERAPEUTICS INC
  • Approval Date :

    27-Nov-23
  • NCE-1 Date :

    27-Nov-27
  • NCE Date :

    27-Nov-28
  • Dosage Form :

    Tablet
  • Strength :

    50mg
  • Therapeutic Category :

    Anticancer
  • Revenue ($M) :

    172

Year-wise Projected Sales ($M) :

  • 2025 :

    146
  • 2026 :

    400
  • 2027 :

    533
  • 2028 :

    671
  • 2029 :

    806
  • 2030 :

    974
  • 2031 :

    1,063
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?